NCT06940440View on ClinicalTrials.gov

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2028

Conditions
Advanced Or Metastatic Merkel Cell Carcinoma
Interventions
DRUG

IFx-Hu2.0

"Therapeutic Classification:~• Innate immune agonist~Route of Administration:~• Intralesional"

DRUG

Pembrolizumab

"Therapeutic Classification:~• Immunotherapy (Immune checkpointinhibitor)~Route of administration:~• Intravenous (IV) infusion"

Trial Locations (2)

33612

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute, Tampa

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
lead

TuHURA Biosciences, Inc.

INDUSTRY

NCT06940440 - IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | Biotech Hunter | Biotech Hunter